Irene Oi-lin Ng

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1212352/irene-oi-lin-ng-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236 papers	16,382 citations	69 h-index	121 g-index
246 ext. papers	18,883 ext. citations	7.9 avg, IF	6.44 L-index

#	Paper	IF	Citations
236	Histone chaperone FACT complex coordinates with HIF to mediate an expeditious transcription program to adapt to poorly oxygenated cancers.. *Cell Reports*, **2022**, 38, 110304	10.6	1
235	Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.. *Journal of Hepatology*, **2022**,	13.4	1
234	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer.. *Nature Communications*, **2022**, 13, 954	17.4	5
233	Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.. *Journal of Hepatology*, **2021**,	13.4	7
232	Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma. *Hepatology*, **2021**,	11.2	1
231	Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. *Annals of the New York Academy of Sciences*, **2021**,	6.5	1
230	Lymphoepithelioma-like neoplasm of the biliary tract with 'probable low malignant potential'. *Histopathology*, **2021**,	7.3	1
229	RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β. *Nature Communications*, **2021**, 12, 1518	17.4	12
228	EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. *Cancer Research*, **2021**, 81, 3229-3240	10.1	11
227	Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling. *Cancer Research*, **2021**, 81, 3679-3692	10.1	3
226	Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. *Nature Communications*, **2021**, 12, 3684	17.4	25
225	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. *Hepatology Communications*, **2021**,	6	3
224	Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. *Hepatology*, **2021**, 73, 23-40	11.2	16
223	RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. *Journal of Hepatology*, **2021**, 74, 360-371	13.4	11
222	Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. *Cell Reports*, **2021**, 34, 108676	10.6	12
221	The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. *Cell Death and Disease*, **2021**, 12, 148	9.8	9
220	Cellular heterogeneity and plasticity in liver cancer. *Seminars in Cancer Biology*, **2021**,	12.7	13

219	Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. *Communications Biology*, **2021**, 4, 888	6.7	2
218	Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species. *Hepatology*, **2021**, 74, 776-796	11.2	3
217	Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1.. *Cell and Bioscience*, **2021**, 11, 217	9.8	2
216	Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. *BMC Cancer*, **2020**, 20, 403	4.8	3
215	Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma. *Journal of Pathology*, **2020**, 252, 65-76	9.4	2
214	Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma. *Oncogene*, **2020**, 39, 4061-4076	9.2	6
213	Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. *British Journal of Cancer*, **2020**, 122, 1428-1440	8.7	22
212	NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. *Cancer Letters*, **2020**, 476, 48-56	9.9	20
211	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. *Gastroenterology*, **2020**, 159, 609-623	13.3	42
210	Joining the dots for better liver cancer treatment. *Nature Reviews Gastroenterology and Hepatology* , **2020**, 17, 74-75	24.2	7
209	Exosomes derived from V□-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity. *Science Translational Medicine*, **2020**, 12,	17.5	15
208	Centrosomal protein TAX1BP2 inhibits centrosome-microtubules aberrations induced by hepatitis B virus X oncoprotein. *Cancer Letters*, **2020**, 492, 147-161	9.9	3
207	Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. *Hepatology*, **2020**, 72, 155-168	11.2	31
206	Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. *Gut*, **2020**, 69, 329-342	19.2	17
205	Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 423	12.8	26
204	Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. *Cancer Letters*, **2019**, 459, 176-185	9.9	55
203	Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. *International Journal of Cancer*, **2019**, 145, 1860-1873	7.5	9
202	Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 2502-2517	11.2	44

201	Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut*, **2019**, 68, 916-927	19.2	117
200	Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. *Nature Communications*, **2019**, 10, 4681	17.4	100
199	Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. *Cell Death and Disease*, **2019**, 10, 934	9.8	45
198	C-terminal truncated HBx protein activates caveolin-1/LRP6/-catenin/FRMD5 axis in promoting hepatocarcinogenesis. *Cancer Letters*, **2019**, 444, 60-69	9.9	16
197	APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. *Molecular Carcinogenesis*, **2019**, 58, 643-653	5	7
196	Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 1768-1786	11.2	63
195	HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 2013-2030	11.2	32
194	IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. *Cancer Research*, **2018**, 78, 2332-2342	10.1	43
193	Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/-catenin pathway. *Cell Death and Differentiation*, **2018**, 25, 1426-1441	12.7	30
192	Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts-An immunohistochemical study. *Clinical Transplantation*, **2018**, 32, e13203	3.8	2
191	Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 137-151	24.2	239
190	Liver allograft biopsies with histological cholestasis: a clinicopathological study of 254 cases from a single centre. *Journal of Clinical Pathology*, **2018**, 71, 72-78	3.9	2
189	RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology*, **2018**, 67, 2254-2270	11.2	599
188	Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. *Oncogenesis*, **2018**, 7, 44	6.6	19
187	SENP1 promotes hypoxia-induced cancer stemness by HIF-1deSUMOylation and SENP1/HIF-1 positive feedback loop. *Gut*, **2017**, 66, 2149-2159	19.2	84
186	Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. *Journal of Hepatology*, **2017**, 67, 758-769	13.4	83
185	Hepatic IFIT3 predicts interferon-therapeutic response in patients of hepatocellular carcinoma. *Hepatology*, **2017**, 66, 152-166	11.2	38
184	Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-B pathway. *Cancer Letters*, **2017**, 411, 150-161	9.9	18

183	Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma - an immunohistochemical study. *Diagnostic Pathology*, **2017**, 12, 56	3	4
182	Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. *Journal of Clinical Investigation*, **2017**, 127, 1856-1872	15.9	64
181	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. *Nature Communications*, **2017**, 8, 517	17.4	179
180	Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration. *Nature Communications*, **2017**, 8, 1185	17.4	12
179	Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. *Journal of Hepatology*, **2017**, 67, 979-990	13.4	74
178	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. *Cancer Letters*, **2017**, 403, 330-338	9.9	28
177	Oval Cells Contribute to Fibrogenesis of Marginal Liver Grafts under Stepwise Regulation of Aldose Reductase and Notch Signaling. *Theranostics*, **2017**, 7, 4879-4893	12.1	8
176	miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. *Oncotarget*, **2017**, 8, 11343-11355	3.3	36
175	C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. *Oncotarget*, **2017**, 8, 23507-23516	3.3	28
174	Dishevelled-3 phosphorylation is governed by HIPK2/PP1C/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma. *Oncotarget*, **2017**, 8, 39430-39442	3.3	4
173	Immunoglobulin G4-related sclerosing disease involving the mandible. *Hong Kong Medical Journal*, **2017**, 23, 534-6	0.7	
172	Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations. *Annals of the Rheumatic Diseases*, **2016**, 75, 891-8	2.4	19
171	Mechanisms through Which Hypoxia-Induced Caveolin-1 Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma. *Cancer Research*, **2016**, 76, 7242-7253	10.1	29
170	The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: A single-center experience. *Medicine (United States)*, **2016**, 95, e4133	1.8	22
169	Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. *Liver International*, **2016**, 36, 737-45	7.9	43
168	NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma. *Clinical Cancer Research*, **2016**, 22, 3105-17	12.9	45
167	Transketolase counteracts oxidative stress to drive cancer development. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E725-34	11.5	138
166	Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. *Journal of Hepatology*, **2016**, 64, 1256-64	13.4	26

165	RhoE/ROCK2 regulates chemoresistance through NF-B/IL-6/ STAT3 signaling in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 41445-41459	3.3	22
164	Hormonal control of the metabolic machinery of hepatocellular carcinoma. *Hepatobiliary Surgery and Nutrition*, **2016**, 5, 195-7	2.1	2
163	Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/catenin signaling. *Oncotarget*, **2016**, 7, 29371-86	3.3	58
162	Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. *Hepatology*, **2016**, 64, 797-813	11.2	119
161	Down-regulation of TIMP2 by HIF-1/miR-210/HIF-3 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. *Hepatology*, **2016**, 64, 473-87	11.2	72
160	Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. *Hepatology*, **2016**, 63, 474-87	11.2	103
159	Molecular Pathogenesis of Hepatocellular Carcinoma. *Liver Cancer*, **2016**, 5, 290-302	9.1	47
158	Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. *Cell Reports*, **2016**, 15, 1175-89	10.6	183
157	PAK4 Phosphorylates p53 at Serine 215 to Promote Liver Cancer Metastasis. *Cancer Research*, **2016**, 76, 5732-5742	10.1	20
156	TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. *Frontiers of Medicine*, **2015**, 9, 322-30	12	46
155	MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. *Frontiers of Medicine*, **2015**, 9, 331-43	12	37
154	Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. *Liver International*, **2015**, 35, 1597-606	7.9	114
153	Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. *Human Molecular Genetics*, **2015**, 24, 274-84	5.6	28
152	Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. *Hepatology*, **2015**, 62, 534-45	11.2	103
151	Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability. *Oncotarget*, **2015**, 6, 20959-63	3.3	36
150	PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. *Oncotarget* , **2015**, 6, 10880-92	3.3	44
149	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. *Arthritis Research and Therapy*, **2015**, 17, 67	5.7	5
148	uGPA: unified Gene Pathway Analyzer package for high-throughput genome-wide screening data provides mechanistic overview on human diseases. *Clinica Chimica Acta*, **2015**, 441, 105-8	6.2	2

147	MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. *Oncotarget*, **2015**, 6, 13658-70	3.3	63
146	Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. *Oncotarget*, **2015**, 6, 20964-76	3.3	29
145	Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis. *Oncotarget*, **2015**, 6, 43483-95	3.3	9
144	Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. *Hepatology*, **2014**, 60, 179-91	11.2	126
143	The impact of hypoxia in hepatocellular carcinoma metastasis. *Frontiers of Medicine*, **2014**, 8, 33-41	12	52
142	Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. *Hepatology*, **2014**, 60, 1645-58	11.2	146
141	SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma. *Molecular Oncology*, **2014**, 8, 366-77	7.9	26
140	The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma. *Human Pathology*, **2014**, 45, 1847-58	3.7	22
139	Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. *PLoS ONE*, **2014**, 9, e115036	3.7	52
138	Requirement of CRTC1 coactivator for hepatitis B virus transcription. *Nucleic Acids Research*, **2014**, 42, 12455-68	20.1	18
137	Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma. *Journal of Pathology*, **2014**, 233, 51-60	9.4	4
136	Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. *BMC Complementary and Alternative Medicine*, **2014**, 14, 303	4.7	11
135	Histological Mimicker of Hepatocellular Carcinoma in the Liver **2014**, 19, 305-308		
134	Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. *Cancer Immunology Research*, **2014**, 2, 1209-19	12.5	28
133	Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents. *Molecular Cancer Therapeutics*, **2014**, 13, 3001-12	6.1	23
132	Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. *Cancer Letters*, **2013**, 338, 101-9	9.9	48
131	C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. *Hepatology*, **2013**, 57, 131-9	11.2	107
130	RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. *Hepatology*, **2013**, 57, 152-61	11.2	37

129	Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. *American Journal of Human Genetics*, **2013**, 92, 41-51	11	144
128	Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins. *Frontiers of Medicine*, **2013**, 7, 231-41	12	15
127	PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. *Nature Communications*, **2013**, 4, 1618	17.4	22
126	Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. *Hepatology*, **2013**, 57, 637-47	11.2	76
125	Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. *Journal of Clinical Pathology*, **2013**, 66, 392-8	3.9	20
124	EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. *PLoS ONE*, **2013**, 8, e68226	3.7	41
123	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. *Hepatobiliary Surgery and Nutrition*, **2013**, 2, 34-6	2.1	
122	Epigenetic Regulation of EZH2 and Its Targeted MicroRNAs **2013**, 33-61		
121	Reply to: Deregulation of microRNAs expression occurs in stages of multistep hepatocarcinogenesis: Why is it different? *Journal of Hepatology*, **2012**, 56, 1426-1427	13.4	
120	The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2. *Hepatology*, **2012**, 56, 1770-81	11.2	10
119	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. *Cancer Research*, **2012**, 72, 4394-404	10.1	152
118	Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. *Future Oncology*, **2012**, 8, 1525-8	3.6	7
117	CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells. *PLoS ONE*, **2012**, 7, e42210	3.7	21
116	Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. *Journal of Pathology*, **2012**, 226, 645-53	9.4	61
115	Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. *Hepatology*, **2012**, 55, 1453-61	11.2	79
114	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. *Hepatology*, **2012**, 56, 622-31	11.2	227
113	Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. *Journal of Biological Chemistry*, **2012**, 287, 26104-14	5.4	12
112	Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. *Journal of the National Cancer Institute*, **2012**, 104, 1796-807	9.7	65

111	Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. *PLoS ONE*, **2012**, 7, e36565	3.7	53
110	Genomics of Hepatocellular Carcinoma **2012**, 45-78		
109	The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. *Gastroenterology*, **2011**, 140, 322-31	13.3	252
108	Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. *Journal of Hepatology*, **2011**, 54, 1177-84	13.4	117
107	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. *Cell Stem Cell*, **2011**, 9, 50-63	18	463
106	Ketamine-induced cholangiopathy: a case report. *American Journal of Gastroenterology*, **2011**, 106, 1004-5	5.7	22
105	Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. *PLoS ONE*, **2011**, 6, e16984	3.7	25
104	Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. *PLoS ONE*, **2011**, 6, e25547	3.7	12
103	Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. *PLoS ONE*, **2011**, 6, e28798	3.7	53
102	Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. *Liver International*, **2011**, 31, 1494-504	7.9	95
101	Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2011**, 23, 245-53	3.8	16
100	Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. *Liver Transplantation*, **2011**, 17, 115-21	4.5	25
99	Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. *Hepatology*, **2011**, 53, 160-70	11.2	80
98	Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. *Hepatology*, **2011**, 53, 1558-69	11.2	77
97	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16369-74	11.5	296
96	Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. *Cancer Research*, **2011**, 71, 2949-58	10.1	56
95	Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?. *Cancer Research*, **2011**, 71, 3701-8	10.1	86
94	ELF1 is associated with systemic lupus erythematosus in Asian populations. *Human Molecular Genetics*, **2011**, 20, 601-7	5.6	58

93	Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery. *PLoS ONE*, **2011**, 6, e16702	3.7	22
92	Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. *PLoS ONE*, **2011**, 6, e19804	3.7	33
91	Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. *Liver International*, **2010**, 30, 65-75	7.9	26
90	Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. *Liver International*, **2010**, 30, 139-48	7.9	16
89	RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it. *Liver International*, **2010**, 30, 642-56	7.9	35
88	Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. *Liver International*, **2010**, 30, 1315-23	7.9	18
87	N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H. *Journal of Cell Science*, **2010**, 123, 1438-48	5.3	28
86	Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. *PLoS Genetics*, **2010**, 6, e1000841	6	316
85	Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. *Gastroenterology*, **2010**, 139, 1397-407	13.3	27
84	Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2010**, 1806, 138-45	11.2	27
83	MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. *Hepatology*, **2010**, 52, 1731-40	11.2	207
82	Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. *PLoS ONE*, **2009**, 4, e5572	3.7	40
81	Protein-losing enteropathy due to T-cell large granular lymphocyte leukemia. *Journal of Clinical Oncology*, **2009**, 27, 2097-8	2.2	3
80	Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. *Hepatology*, **2009**, 49, 1583-94	11.2	110
79	HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. *International Journal of Cancer*, **2009**, 124, 1811-9	7.5	24
78	Role and significance of focal adhesion proteins in hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, **2009**, 24, 520-30	4	30
77	Liver cancer stem cells: implications for a new therapeutic target. *Liver International*, **2009**, 29, 955-65	7.9	64
76	MicroRNA expression, survival, and response to interferon in liver cancer. *New England Journal of Medicine*, **2009**, 361, 1437-47	59.2	675

75	Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. *PLoS ONE*, **2009**, 4, e6566	3.7	23
74	Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. *Cancer Research*, **2008**, 68, 5988-96	10.1	38
73	Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer. *Cancer Research*, **2008**, 68, 9194-201	10.1	19
72	Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. *PLoS ONE*, **2008**, 3, e2779	3.7	55
71	Gene expression profiles of different stages of hepatocarcinogenesis. *Journal of Gastroenterology and Hepatology (Australia)*, **2008**, 23, 1-3	4	1
70	Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. *International Journal of Cancer*, **2008**, 123, 1043-52	7.5	34
69	Identification and characterization of tumorigenic liver cancer stem/progenitor cells. *Gastroenterology*, **2007**, 132, 2542-56	13.3	991
68	Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. *Hepatology*, **2007**, 45, 1129-38	11.2	85
67	Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. *Proteins: Structure, Function and Bioinformatics*, **2007**, 67, 1154-66	4.2	29
66	Liver transplantation for combined hepatocellular cholangiocarcinoma. *Asian Journal of Surgery*, **2007**, 30, 143-6	1.6	38
65	P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. *Cancer Research*, **2007**, 67, 3601-8	10.1	105
64	Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. *Hepatology*, **2006**, 44, 881-90	11.2	21
63	Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma. *Clinical Cancer Research*, **2006**, 12, 6617-25	12.9	19
62	Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. *Cancer Research*, **2006**, 66, 8367-72	10.1	88
61	A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. *Hemoglobin*, **2006**, 30, 263-74	0.6	31
60	Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. *Gastroenterology*, **2006**, 131, 1218-27	13.3	98
59	Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. *FEBS Letters*, **2006**, 580, 191-8	3.8	23
58	Osteomyelitis with proliferative periostitis: an unusual case. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics*, **2006**, 102, e14-9		19

57	Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. *Journal of Pathology*, **2006**, 208, 372-80	9.4	47
56	The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. *Experimental Cell Research*, **2005**, 304, 1-15	4.2	30
55	HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. *Oncogene*, **2005**, 24, 1607-14	9.2	79
54	Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. *Surgery*, **2005**, 137, 403-10	3.6	182
53	Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transplantation*, **2005**, 11, 1086-92	4.5	467
52	Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. *Archives of Surgery*, **2005**, 140, 450-7; discussion 457-8		178
51	Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. *Cancer Research*, **2005**, 65, 8861-8	10.1	129
50	Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 15207-12	11.5	99
49	The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. *Nucleic Acids Research*, **2005**, 33, 1859-73	20.1	79
48	Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. *Archives of Surgery*, **2004**, 139, 193-200		30
47	Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. *Clinical Cancer Research*, **2004**, 10, 4140-9	12.9	75
46	Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. *American Journal of Gastroenterology*, **2004**, 99, 2032-7	0.7	47
45	HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. *Hepatology*, **2004**, 39, 1694-701	11.2	198
44	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. *Liver Transplantation*, **2004**, 10, 557-63	4.5	26
43	Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. *Journal of Gastrointestinal Surgery*, **2004**, 8, 794-804; discussion 804-5	3.3	27
42	High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. *Human Pathology*, **2004**, 35, 1324-31	3.7	57
41	Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. *Annals of Surgery*, **2004**, 239, 194-201	7.8	175
40	Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells **2004**, 11, 920		0

39	Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. *Carcinogenesis*, **2003**, 24, 1729-36	4.6	41
38	Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. *Annals of Surgery*, **2003**, 237, 376-83	7.8	78
37	Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts. *Liver Transplantation*, **2003**, 9, 425-32	4.5	53
36	Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. *Liver Transplantation*, **2003**, 9, 827-32	4.5	32
35	Variations in clinical presentations of the simple bone cyst: report of cases. *Journal of Oral and Maxillofacial Surgery*, **2003**, 61, 1487-91	1.8	32
34	High frequency of chimerism in transplanted livers. *Hepatology*, **2003**, 38, 989-998	11.2	99
33	Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. *International Journal of Cancer*, **2003**, 107, 22-9	7.5	121
32	Cholangiocarcinoma in liver cirrhosis. *Journal of Gastroenterology and Hepatology (Australia)*, **2003**, 18, 337-41	4	11
31	Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. *Journal of Pathology*, **2003**, 199, 345-53	9.4	112
30	Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinomas from chinese patients. *Human Pathology*, **2003**, 34, 699-705	3.7	10
29	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. *Journal of Hepatology*, **2003**, 39, 850-5	13.4	49
28	Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. *Journal of Biological Chemistry*, **2003**, 278, 10824-30	5.4	151
27	High frequency of chimerism in transplanted livers. *Hepatology*, **2003**, 38, 989-98	11.2	21
26	Reversal of protein-losing enteropathy by liver transplantation. *Journal of Clinical Gastroenterology*, **2003**, 36, 86-7	3	8
25	Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. *Cancer Research*, **2003**, 63, 7646-51	10.1	141
24	High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. *Cancer*, **2002**, 94, 3179-85	6.4	47
23	Intraoperative iatrogenic rupture of hepatocellular carcinoma. *World Journal of Surgery*, **2002**, 26, 348-52	3.3	10
22	Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. *Cancer Chemotherapy and Pharmacology*, **2002**, 49, 78-86	3.5	113

21	Clinicopathologic and prognostic significance of the histologic activity of noncancerous liver tissue in hepatitis B virus-associated hepatocellular carcinoma. *American Journal of Clinical Pathology*, **2002**, 117, 411-8	1.9	3
20	Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. *Journal of Clinical Oncology*, **2002**, 20, 1775-85	2.2	238
19	Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. *Life Sciences*, **2002**, 70, 1677-90	6.8	16
18	Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. *Cancer Letters*, **2002**, 175, 27-38	9.9	96
17	Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. *International Journal of Cancer*, **2001**, 93, 393-400	7.5	27
16	Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. *American Journal of Clinical Pathology*, **2001**, 116, 838-45	1.9	145
15	Low molecular weight heparin-induced liver toxicity. *Journal of Clinical Pharmacology*, **2001**, 41, 691-4	2.9	25
14	Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. *American Journal of Surgery*, **2001**, 182, 298-304	2.7	114
13	Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. *Human Pathology*, **2001**, 32, 778-84	3.7	56
12	Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. *Cancer Letters*, **2001**, 172, 7-15	9.9	39
11	Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. *Journal of Clinical Oncology*, **2001**, 19, 3037-44	2.2	137
10	Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. *Annals of Surgery*, **2001**, 233, 227-35	7.8	190
9	Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. *Annals of Surgery*, **2001**, 233, 276-81	7.8	110
8	Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. *Annals of Surgery*, **2001**, 234, 63-70	7.8	455
7	Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. *Cancer*, **2000**, 89, 500-507	6.4	576
6	Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma **2000**, 89, 500		12
5	Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. *Journal of Gastroenterology and Hepatology (Australia)*, **1998**, 13, 34-40	4	98
4	Imaging of follicular dendritic cell tumours of the liver. *Journal of Gastroenterology and Hepatology (Australia)*, **1998**, 13, 1146-51	4	2

3	Prognostic significance of pathological and biological factors in hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, **1998**, 13, 666-70	4	26
2	Molecular and cellular pathology of hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, **1998**, 13, S299-S303	4	
1	Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. *Hepatology*, **1990**, 11, 815-8	11.2	140